跳转至内容
Merck
CN
  • Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.

Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.

BJU international (2014-01-29)
Prue Cormie, Daniel A Galvão, Nigel Spry, David Joseph, Raphael Chee, Dennis R Taaffe, Suzanne K Chambers, Robert U Newton
摘要

To determine if supervised exercise minimises treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy (ADT). This is the first study to date that has investigated the potential role of exercise in preventing ADT toxicity rather than recovering from established toxicities. Sixty-three men scheduled to receive ADT were randomly assigned to a 3-month supervised exercise programme involving aerobic and resistance exercise sessions commenced within 10 days of their first ADT injection (32 men) or usual care (31 men). The primary outcome was body composition (lean and fat mass). Other study outcomes included bone mineral density, physical function, blood biomarkers of chronic disease risk and bone turnover, general and prostate cancer-specific quality of life, fatigue and psychological distress. Outcomes were compared between groups using analysis of covariance adjusted for baseline values. Compared to usual care, a 3-month exercise programme preserved appendicular lean mass (P = 0.019) and prevented gains in whole body fat mass, trunk fat mass and percentage fat with group differences of -1.4 kg (P = 0.001), -0.9 kg (P = 0.008) and -1.3% (P < 0.001), respectively. Significant between-group differences were also seen favouring the exercise group for cardiovascular fitness (peak oxygen consumption 1.1 mL/kg/min, P = 0.004), muscular strength (4.0-25.9 kg, P ≤ 0.026), lower body function (-1.1 s, P < 0.001), total cholesterol: high-density lipoprotein-cholesterol ratio (-0.52, P = 0.028), sexual function (15.2, P = 0.028), fatigue (3.1, P = 0.042), psychological distress (-2.2, P = 0.045), social functioning (3.8, P = 0.015) and mental health (3.6-3.8, P ≤ 0.022). There were no significant group differences for any other outcomes. Commencing a supervised exercise programme involving aerobic and resistance exercise when initiating ADT significantly reduced treatment toxicity, while improving social functioning and mental health. Concurrent prescription of supervised exercise when initiating ADT is therefore advised to minimise morbidity associated with severe hypogonadism.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
胆固醇, Sigma Grade, ≥99%
Sigma-Aldrich
胆固醇, powder, BioReagent, suitable for cell culture, ≥99%
Sigma-Aldrich
肌酸酐, anhydrous, ≥98%
Sigma-Aldrich
SyntheChol ® NS0 补充, 500 ×, synthetic cholesterol, animal component-free, sterile-filtered, aqueous solution, suitable for cell culture
Sigma-Aldrich
胆固醇, from sheep wool, ≥92.5% (GC), powder
Supelco
胆固醇, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
胆固醇 溶液, certified reference material, 10 mg/mL in chloroform
Supelco
肌酐, Pharmaceutical Secondary Standard; Certified Reference Material
SAFC
胆固醇, from sheep wool, Controlled origin, meets USP/NF testing specifications
Sigma-Aldrich
胆固醇, tested according to Ph. Eur.